Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Bavarian Nordic tiene un patrimonio de accionistas total de DKK10.3B y una deuda total de DKK17.0M, lo que sitúa su ratio deuda-patrimonio en 0.2%. Sus activos y pasivos totales son DKK14.4B y DKK4.0B respectivamente. El BAIT de Bavarian Nordic es de DKK2.2B, por lo que su ratio de cobertura de intereses es de -42.8. Tiene efectivo e inversiones a corto plazo que ascienden a DKK1.9B.

Información clave

0.2%

Ratio deuda-patrimonio

kr.16.58m

Deuda

Ratio de cobertura de intereses	-29.9x
Efectivo	kr.2.29b
Patrimonio	kr.10.17b
Total pasivo	kr.3.45b
Activos totales	kr.13.62b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK5.4B) de BAVAC superan a sus pasivos a corto plazo (DKK2.8B).

Pasivo a largo plazo: Los activos a corto plazo de BAVAC (DKK5.4B) superan a sus pasivos a largo plazo (DKK1.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BAVAC tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de BAVAC ha pasado de 29.7% a 0.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de BAVAC está bien cubierta por el flujo de caja operativo (6565%).

Cobertura de intereses: BAVAC gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

High number of new directors

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

High number of new directors

Bavarian Nordic A/S announced a financing transaction

Third quarter 2021 earnings released: kr.1.30 loss per share (vs kr.0.50 profit in 3Q 2020)

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

First quarter 2021 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS kr.5.14 (vs kr.10.74 loss in FY 2019)

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

New 90-day high: kr.206

Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Bavarian Nordic A/S Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma